Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

A Strezova; J Diez-Domingo; K Al Shawafi; JC Tinoco; M Shi; P Pirrotta; A Mwakingwe-Omari; M Adams; A Ahonen; C Andrews; E Athan; JF Barbagómez; P Barbanti; E Barberan; A Baty; N Bengtsson; J Berger-Roscher; KB Blom; J Beytout; L Boucher; C Boutry; A Boye; F Brault; L Breger; CB Cuixart; C Caso; C Cerna; HS Cheng; HJ Cheong; EJ Choo; C Cunha; AL Cunningham; D Curiac; B Daguzan; A Dahmen; S Datta; MG Desole; ED Paolo; M Dionne; P Dite; J Dutz; J Earl; T Eckermann; W Ellison; J Eremenko; M Esen; T Eto; XF Fabré; C Farrington; M Ferguson; PA Ferrand; M Finneran; D Francyk; M Freedman; G Freeman; AT Freire; P Gal; JS Gauthier; B Gerlach; W Ghesquiere; I Gorfinkel; C Grigat; J Grosskopf; M Hamann; P Hanrion; P Hartley; A Hastie; K Heaton; A Himpel-Boenninghoff; T Horacek; DSC Hui; Y Huong; SJ Hwang; G Icardi; G Illies; J Irimajiri; W Jacob; A Jambrecina; TJ Avelino-Silva; G Kalema; HY Kim; C Klein; U Kleinecke; HJ Koenig; S Kokko; P Kosina; S Koski; P Koskinen; M Kropp; R Kuroki; O Laajalahti; P Lachance; J Lee; JS Lee; P Levins; R Lipetz; B Liu; CS Liu; M Lundvall; L Magimaiseelan

Journal article

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

A Strezova, J Diez-Domingo, K Al Shawafi, JC Tinoco, M Shi, P Pirrotta, A Mwakingwe-Omari, M Adams, A Ahonen, C Andrews, E Athan, JF Barbagómez, P Barbanti, E Barberan, A Baty, N Bengtsson, J Berger-Roscher, KB Blom, J Beytout, L Boucher Show all

Open Forum Infectious Diseases | Published : 2022

DOI: 10.1093/ofid/ofac485

Open access

Download PDF

Abstract

Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.